11 February 2021

Practical Tips Monetization and Licensing Opportunities in the Life Sciences

Patents and other forms of IP have traditionally been the main way pharmaceutical and biotech companies have secured markets and ensured freedom to operate. 2020 has seen a shift towards licensing deals from some of the leading names in Life Sciences, will this trend continue?

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers

Practical Tips Monetization and Licensing Opportunities in the Life Sciences

Editor's picks

Editor's picks

More features